Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169284913> ?p ?o ?g. }
- W2169284913 endingPage "41.e22" @default.
- W2169284913 startingPage "41.e11" @default.
- W2169284913 abstract "To analyze the cytotoxic action of temsirolimus using 3 established human bladder cancer cell lines and to assess whether temsirolimus potentiates the anticancer activity of gemcitabine and cisplatin.Temsirolimus (500, 1,000, 2,000, and 4,000 nM), in isolation, and combined with gemcitabine (100 nM) and cisplatin (2.5 µg/ml), was given to 5637, T24, and HT1376 bladder cancer cell lines. Cell proliferation, autophagy, early apoptosis, and cell cycle distribution were analyzed after a 72-hour period. The expression of mammalian target of rapamycin baseline, Akt, and their phosphorylated forms, before and after treatment with temsirolimus, was evaluated by immunoblotting.Temsirolimus slightly decreased the bladder cancer cell proliferation in all 3 cell lines. No significant differences in the expression of mammalian target of rapamycin, Akt, and their phosphorylated forms because of temsirolimus exposure were found in the 3 cell lines. As part of a combined regime along with gemcitabine, and especially with cisplatin, there was a more pronounced antiproliferative effect. This pattern of response was similar to the other parameters analyzed (increased autophagy and apoptosis). Also, in the combined regime, an enhanced cell cycle arrest in the G0/G1 phase was observed. The non-muscle invasive 5637 bladder cancer cell line was most sensitive to both combinations.Temsirolimus makes a moderate contribution in terms of cell proliferation, apoptosis, and autophagy. However, it does potentiate the activity of gemcitabine and particularly cisplatin. Therefore, cisplatin- or gemcitabine-based chemotherapy regimen used in combination with temsirolimus to treat bladder cancer represents a novel and valuable treatment option, which should be tested for future studies in urinary bladder xenograft models." @default.
- W2169284913 created "2016-06-24" @default.
- W2169284913 creator A5020773278 @default.
- W2169284913 creator A5021183665 @default.
- W2169284913 creator A5021567959 @default.
- W2169284913 creator A5052493209 @default.
- W2169284913 creator A5075468536 @default.
- W2169284913 creator A5082744894 @default.
- W2169284913 creator A5086970300 @default.
- W2169284913 creator A5083485693 @default.
- W2169284913 date "2014-01-01" @default.
- W2169284913 modified "2023-10-01" @default.
- W2169284913 title "Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines" @default.
- W2169284913 cites W1498637512 @default.
- W2169284913 cites W1965766554 @default.
- W2169284913 cites W1970322471 @default.
- W2169284913 cites W1970379448 @default.
- W2169284913 cites W1976559692 @default.
- W2169284913 cites W1979177925 @default.
- W2169284913 cites W1982401280 @default.
- W2169284913 cites W1986428317 @default.
- W2169284913 cites W1988338260 @default.
- W2169284913 cites W1989990191 @default.
- W2169284913 cites W1990883066 @default.
- W2169284913 cites W1991718833 @default.
- W2169284913 cites W1992756057 @default.
- W2169284913 cites W1994192011 @default.
- W2169284913 cites W2000570054 @default.
- W2169284913 cites W2007665175 @default.
- W2169284913 cites W2009599943 @default.
- W2169284913 cites W2018774200 @default.
- W2169284913 cites W2019043300 @default.
- W2169284913 cites W2021343953 @default.
- W2169284913 cites W2027880004 @default.
- W2169284913 cites W2029098356 @default.
- W2169284913 cites W2053874502 @default.
- W2169284913 cites W2065508488 @default.
- W2169284913 cites W2075150946 @default.
- W2169284913 cites W2092661658 @default.
- W2169284913 cites W2095445076 @default.
- W2169284913 cites W2097829773 @default.
- W2169284913 cites W2101967561 @default.
- W2169284913 cites W2102036384 @default.
- W2169284913 cites W2110260685 @default.
- W2169284913 cites W2116293130 @default.
- W2169284913 cites W2117692326 @default.
- W2169284913 cites W2119607431 @default.
- W2169284913 cites W2121141015 @default.
- W2169284913 cites W2127046868 @default.
- W2169284913 cites W2128648300 @default.
- W2169284913 cites W2133742377 @default.
- W2169284913 cites W2133934152 @default.
- W2169284913 cites W2134855990 @default.
- W2169284913 cites W2140798553 @default.
- W2169284913 cites W2142765998 @default.
- W2169284913 cites W2146950619 @default.
- W2169284913 cites W2147483024 @default.
- W2169284913 cites W2152823504 @default.
- W2169284913 cites W2158305336 @default.
- W2169284913 cites W2162973874 @default.
- W2169284913 cites W2166232131 @default.
- W2169284913 cites W2320054082 @default.
- W2169284913 cites W2901641357 @default.
- W2169284913 doi "https://doi.org/10.1016/j.urolonc.2013.04.012" @default.
- W2169284913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24035472" @default.
- W2169284913 hasPublicationYear "2014" @default.
- W2169284913 type Work @default.
- W2169284913 sameAs 2169284913 @default.
- W2169284913 citedByCount "21" @default.
- W2169284913 countsByYear W21692849132014 @default.
- W2169284913 countsByYear W21692849132015 @default.
- W2169284913 countsByYear W21692849132016 @default.
- W2169284913 countsByYear W21692849132017 @default.
- W2169284913 countsByYear W21692849132018 @default.
- W2169284913 countsByYear W21692849132019 @default.
- W2169284913 countsByYear W21692849132020 @default.
- W2169284913 countsByYear W21692849132022 @default.
- W2169284913 countsByYear W21692849132023 @default.
- W2169284913 crossrefType "journal-article" @default.
- W2169284913 hasAuthorship W2169284913A5020773278 @default.
- W2169284913 hasAuthorship W2169284913A5021183665 @default.
- W2169284913 hasAuthorship W2169284913A5021567959 @default.
- W2169284913 hasAuthorship W2169284913A5052493209 @default.
- W2169284913 hasAuthorship W2169284913A5075468536 @default.
- W2169284913 hasAuthorship W2169284913A5082744894 @default.
- W2169284913 hasAuthorship W2169284913A5083485693 @default.
- W2169284913 hasAuthorship W2169284913A5086970300 @default.
- W2169284913 hasConcept C121608353 @default.
- W2169284913 hasConcept C126322002 @default.
- W2169284913 hasConcept C143998085 @default.
- W2169284913 hasConcept C183713625 @default.
- W2169284913 hasConcept C190283241 @default.
- W2169284913 hasConcept C2776694085 @default.
- W2169284913 hasConcept C2776820818 @default.
- W2169284913 hasConcept C2778239845 @default.
- W2169284913 hasConcept C2780258809 @default.
- W2169284913 hasConcept C2780352672 @default.
- W2169284913 hasConcept C29537977 @default.